Clinic
Texas Children's Hospital
Texas Children's Hospital was paid $277.28M by Medicaid between Jan 2018 and Dec 2024, across 400 billing codes. Its largest line is 99285, emergency room visit (most serious) — 29% of everything it billed.
33Billing provider infoTEXAS CHILDREN'S HOSPITAL
HOUSTON, TX 77030
HOUSTON, TX 77030
33aNPI1477643690assigned 10/16/2006
33bProvider typeCritical Access Hospital Clinic/Center
28Total paid$277.28M
24GClaims1,753,239
24DCodes billed400
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital Clinic/Center providers in Texas
Rank by total paid#1 of 11
Median peer was paid$716K
This provider vs. median387×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 623 | $63K | |
| 2019 | 414 | $45K | |
| 2020 | 55,223 | $8.69M | |
| 2021 | 368,585 | $51.37M | |
| 2022 | 472,047 | $68.84M | |
| 2023 | 518,587 | $89.34M | |
| 2024incomplete | 337,760 | $58.92M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 29% | 84,138 | 82,633 | $80.49M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 66,205 | 65,501 | $52.69M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.5% | 56,219 | 19,214 | $12.58M |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.9% | 3,610 | 3,558 | $8.12M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 2.9% | 3,241 | 3,169 | $7.95M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.7% | 32,139 | 12,249 | $7.50M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.8% | 72,366 | 71,355 | $4.87M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.7% | 2,821 | 2,779 | $4.65M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.6% | 38,389 | 13,550 | $4.55M |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | 1.6% | 11,574 | 11,419 | $4.40M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 25,162 | 24,160 | $4.19M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.5% | 18,028 | 17,437 | $4.07M |
388 more codes
| G0378 | Hospital observation service, per hour | 1.4% | 5,670 | $3.97M |
| 87632 | 1.3% | 10,739 | $3.67M | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.3% | 16,306 | $3.62M |
| 99283 | Emergency room visit (moderate) | 1.3% | 63,971 | $3.54M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.2% | 2,290 | $3.44M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 3,413 | $3.25M |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 21,400 | $2.99M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 1.0% | 3,633 | $2.88M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 69,365 | $2.44M |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 9,360 | $2.26M |
| 92567 | <1% | 41,504 | $2.03M | |
| 93325 | <1% | 11,269 | $2.02M | |
| 92579 | <1% | 15,702 | $2.01M | |
| 92587 | <1% | 30,639 | $1.83M | |
| 59025 | Fetal non-stress test | <1% | 5,813 | $1.83M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 121,585 | $1.77M |
| 93320 | <1% | 3,807 | $1.52M | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,012 | $1.45M |
| 72082 | <1% | 6,220 | $1.25M | |
| 94010 | <1% | 6,693 | $1.19M | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,552 | $1.14M |
| 76770 | <1% | 4,202 | $1.08M | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,530 | $941K |
| 83735 | <1% | 32,596 | $902K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 77,195 | $875K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 2,149 | $791K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,347 | $749K |
| 94060 | <1% | 2,404 | $718K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,541 | $712K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 148 | $696K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 85,243 | $648K |
| J3490 | Unclassified drugs | <1% | 31,500 | $632K |
| 42830 | <1% | 352 | $617K | |
| A0425 | Ground mileage, per statute mile | <1% | 2,378 | $529K |
| J0475 | Injection, baclofen, 10 mg | <1% | 471 | $503K |
| 81001 | <1% | 12,307 | $501K | |
| 80069 | <1% | 4,855 | $474K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 778 | $469K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 309 | $453K |
| 85046 | <1% | 15,667 | $444K | |
| 73140 | <1% | 3,459 | $439K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 507 | $437K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,032 | $425K |
| 73100 | <1% | 3,274 | $408K | |
| 54161 | <1% | 273 | $397K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 688 | $391K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,782 | $387K |
| 80053 | Comprehensive metabolic panel | <1% | 2,440 | $375K |
| 97597 | <1% | 1,407 | $371K | |
| 82977 | <1% | 13,352 | $345K | |
| 84460 | <1% | 17,207 | $338K | |
| 84100 | <1% | 16,691 | $321K | |
| 82247 | <1% | 14,697 | $315K | |
| 84450 | <1% | 15,911 | $312K | |
| 82248 | <1% | 14,464 | $311K | |
| 93226 | <1% | 584 | $296K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 10,163 | $295K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 29,917 | $291K |
| 92582 | <1% | 2,551 | $270K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 227 | $259K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,179 | $251K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 36,073 | $247K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 25,861 | $237K |
| 72081 | <1% | 1,760 | $236K | |
| 95012 | <1% | 2,475 | $226K | |
| 84075 | <1% | 13,222 | $225K | |
| 74018 | <1% | 2,068 | $214K | |
| 93321 | <1% | 905 | $214K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 29,426 | $213K |
| 72170 | <1% | 1,595 | $211K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,325 | $211K |
| 80197 | <1% | 3,994 | $206K | |
| 76820 | <1% | 1,218 | $190K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 26,471 | $184K |
| 82728 | <1% | 4,454 | $182K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,041 | $181K |
| 92526 | <1% | 1,706 | $177K | |
| 70360 | <1% | 1,214 | $170K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,742 | $169K |
| 99243 | <1% | 25,597 | $162K | |
| 83880 | <1% | 3,083 | $155K | |
| 95812 | <1% | 252 | $154K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,923 | $151K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,311 | $147K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 435 | $145K |
| 17110 | <1% | 1,727 | $143K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,757 | $142K |
| 73090 | <1% | 1,005 | $137K | |
| 73130 | <1% | 1,042 | $137K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,802 | $136K |
| 93225 | <1% | 308 | $127K | |
| 87040 | <1% | 2,015 | $126K | |
| 81025 | <1% | 3,343 | $125K | |
| 93308 | <1% | 530 | $121K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 6,104 | $118K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 2,062 | $117K |
| 92611 | <1% | 608 | $112K | |
| 97165 | <1% | 754 | $111K | |
| 92555 | <1% | 3,479 | $101K | |
| 95782 | <1% | 57 | $100K | |
| 87799 | <1% | 1,071 | $94K | |
| 73564 | <1% | 621 | $92K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 485 | $90K |
| 92018 | <1% | 84 | $90K | |
| 77073 | <1% | 600 | $87K | |
| A0435 | Fixed wing air mileage, per statute mile | <1% | 31 | $85K |
| 74230 | <1% | 447 | $82K | |
| 82040 | <1% | 6,420 | $82K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,053 | $78K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 655 | $77K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 48 | $76K |
| 92557 | <1% | 625 | $75K | |
| 11772 | <1% | 30 | $74K | |
| 75565 | <1% | 264 | $71K | |
| 97162 | <1% | 506 | $71K | |
| A0430 | Ambulance service, conventional air services, transport, one way (fixed wing) | <1% | 31 | $71K |
| 44970 | <1% | 24 | $70K | |
| 73080 | <1% | 450 | $70K | |
| 77072 | <1% | 628 | $68K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 9,751 | $67K |
| 85027 | <1% | 3,536 | $66K | |
| 95117 | <1% | 6,566 | $65K | |
| 87497 | <1% | 767 | $61K | |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) | <1% | 536 | $61K |
| 73610 | <1% | 415 | $60K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 164 | $59K |
| 85007 | <1% | 3,525 | $56K | |
| 83615 | <1% | 3,161 | $56K | |
| 94760 | <1% | 1,795 | $55K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 8,246 | $54K |
| 62369 | <1% | 409 | $52K | |
| 43762 | <1% | 356 | $51K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 7,125 | $47K |
| 77075 | <1% | 191 | $44K | |
| 76801 | <1% | 207 | $43K | |
| 97161 | <1% | 320 | $42K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 81 | $42K |
| 84466 | <1% | 1,678 | $41K | |
| 64642 | <1% | 196 | $40K | |
| 51741 | <1% | 313 | $39K | |
| 87631 | <1% | 230 | $38K | |
| 86140 | <1% | 1,362 | $38K | |
| 73560 | <1% | 339 | $38K | |
| 92552 | <1% | 771 | $37K | |
| 92133 | <1% | 449 | $37K | |
| 83020 | <1% | 1,013 | $36K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,542 | $35K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,387 | $35K |
| 71045 | Radiologic examination, chest; single view | <1% | 444 | $34K |
| 51798 | <1% | 423 | $33K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 827 | $33K |
| 85652 | <1% | 1,772 | $32K | |
| A0382 | Bls routine disposable supplies | <1% | 1,932 | $32K |
| 76981 | <1% | 96 | $32K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,140 | $31K |
| 83540 | <1% | 1,725 | $30K | |
| 93296 | <1% | 144 | $30K | |
| 83690 | <1% | 1,213 | $29K | |
| 73110 | <1% | 173 | $29K | |
| 87070 | <1% | 597 | $28K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 379 | $27K |
| 73630 | <1% | 179 | $27K | |
| 54640 | <1% | 12 | $27K | |
| 92588 | <1% | 218 | $26K | |
| 95873 | <1% | 177 | $25K | |
| 87077 | <1% | 704 | $25K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 129 | $25K |
| 38222 | <1% | 13 | $24K | |
| J0586 | Injection, abobotulinumtoxina, 5 units | <1% | 37 | $24K |
| 97802 | <1% | 1,368 | $24K | |
| 86900 | <1% | 1,739 | $22K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,510 | $21K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,830 | $21K |
| 86901 | <1% | 1,737 | $21K | |
| 86885 | <1% | 1,477 | $20K | |
| 84145 | <1% | 490 | $20K | |
| A0434 | Specialty care transport (sct) | <1% | 41 | $19K |
| 82565 | <1% | 1,420 | $19K | |
| 73070 | <1% | 140 | $19K | |
| 86902 | <1% | 98 | $19K | |
| 96415 | <1% | 176 | $19K | |
| 93886 | <1% | 52 | $18K | |
| 80061 | Lipid panel | <1% | 346 | $18K |
| 73620 | <1% | 130 | $18K | |
| 0074A | <1% | 1,075 | $17K | |
| 85610 | <1% | 1,184 | $17K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,113 | $17K |
| 82784 | <1% | 413 | $17K | |
| 0081A | <1% | 934 | $17K | |
| 95115 | <1% | 1,726 | $16K | |
| 81003 | <1% | 1,081 | $16K | |
| 74019 | <1% | 202 | $16K | |
| 73562 | <1% | 115 | $16K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 13 | $15K |
| 97164 | <1% | 111 | $15K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 158 | $15K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 12 | $15K |
| 54150 | <1% | 39 | $15K | |
| 88304 | <1% | 93 | $14K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 55 | $14K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 190 | $14K |
| 99205 | Prolong outpt/office vis | <1% | 1,841 | $13K |
| 31526 | <1% | 13 | $13K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,842 | $12K |
| 90688 | <1% | 831 | $12K | |
| 93975 | <1% | 41 | $12K | |
| 93356 | <1% | 1,222 | $12K | |
| 0082A | <1% | 677 | $11K | |
| 88185 | <1% | 20 | $11K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 211 | $11K |
| 99245 | <1% | 1,526 | $11K | |
| 93304 | <1% | 26 | $10K | |
| 92083 | <1% | 122 | $10K | |
| 92652 | <1% | 25 | $10K | |
| 71555 | <1% | 12 | $10K | |
| 64643 | <1% | 57 | $9K | |
| 90686 | <1% | 2,239 | $9K | |
| 86356 | <1% | 15 | $9K | |
| 70480 | <1% | 13 | $9K | |
| 84520 | <1% | 720 | $8K | |
| 0054A | <1% | 553 | $8K | |
| 81002 | <1% | 347 | $8K | |
| 86835 | <1% | 15 | $8K | |
| 92585 | <1% | 24 | $8K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 641 | $8K |
| 83970 | <1% | 125 | $8K | |
| 85730 | <1% | 626 | $8K | |
| 97605 | <1% | 44 | $8K | |
| 87081 | <1% | 193 | $8K | |
| 0071A | <1% | 502 | $8K | |
| 80195 | <1% | 149 | $8K | |
| 0111A | <1% | 410 | $7K | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 252 | $7K |
| 73590 | <1% | 60 | $7K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 19 | $6K |
| 86834 | <1% | 13 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 135 | $6K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 381 | $6K |
| 36430 | <1% | 112 | $6K | |
| 80306 | <1% | 137 | $6K | |
| 80305 | <1% | 123 | $6K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 290 | $6K |
| 0072A | <1% | 399 | $6K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 797 | $6K |
| 87449 | <1% | 65 | $6K | |
| 87535 | <1% | 88 | $6K | |
| 81378 | <1% | 17 | $5K | |
| 87186 | <1% | 192 | $5K | |
| 82570 | <1% | 328 | $5K | |
| 0112A | <1% | 316 | $5K | |
| 80329 | <1% | 118 | $5K | |
| 0124A | <1% | 296 | $5K | |
| 86807 | <1% | 32 | $5K | |
| 76885 | <1% | 46 | $5K | |
| 82043 | <1% | 290 | $5K | |
| 73000 | <1% | 25 | $5K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,659 | $5K |
| 76821 | <1% | 32 | $5K | |
| 96409 | <1% | 32 | $5K | |
| 86923 | <1% | 64 | $4K | |
| 82010 | <1% | 130 | $4K | |
| 82610 | <1% | 188 | $4K | |
| 87340 | <1% | 127 | $4K | |
| 76827 | <1% | 33 | $4K | |
| 82805 | <1% | 40 | $4K | |
| 85397 | <1% | 38 | $4K | |
| 99242 | <1% | 491 | $4K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 40 | $4K |
| 92523 | <1% | 26 | $4K | |
| 97804 | <1% | 203 | $4K | |
| 0154A | <1% | 189 | $4K | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 197 | $4K |
| 84134 | <1% | 184 | $4K | |
| 85240 | <1% | 38 | $4K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 227 | $4K |
| 92550 | <1% | 37 | $4K | |
| 0083A | <1% | 230 | $4K | |
| 88271 | <1% | 13 | $4K | |
| 88237 | <1% | 15 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 230 | $3K |
| 83021 | <1% | 59 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 246 | $3K |
| 92553 | <1% | 53 | $3K | |
| 92524 | <1% | 24 | $3K | |
| 87147 | <1% | 111 | $3K | |
| 95076 | <1% | 13 | $3K | |
| 93786 | <1% | 48 | $3K | |
| 88275 | <1% | 13 | $3K | |
| 82803 | <1% | 41 | $3K | |
| 84550 | <1% | 226 | $3K | |
| 85520 | <1% | 46 | $3K | |
| 36591 | <1% | 41 | $3K | |
| 84478 | <1% | 84 | $3K | |
| 92556 | <1% | 39 | $3K | |
| 82962 | <1% | 6,192 | $3K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 3,289 | $3K |
| 85246 | <1% | 38 | $3K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 48 | $3K |
| 84439 | <1% | 94 | $3K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 407 | $2K |
| 86357 | <1% | 27 | $2K | |
| 86355 | <1% | 27 | $2K | |
| 86359 | <1% | 27 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 67 | $2K |
| 86360 | <1% | 12 | $2K | |
| 85660 | <1% | 94 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 299 | $2K |
| 90837 | Psychotherapy session, about an hour | <1% | 72 | $2K |
| 97168 | <1% | 13 | $2K | |
| 90656 | <1% | 353 | $2K | |
| 86592 | <1% | 85 | $2K | |
| 86803 | <1% | 55 | $2K | |
| 51784 | <1% | 25 | $2K | |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 25 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 5,760 | $2K |
| 88184 | <1% | 15 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 274 | $2K |
| 87185 | <1% | 60 | $2K | |
| 81382 | <1% | 17 | $1K | |
| 87536 | <1% | 12 | $1K | |
| 80320 | <1% | 53 | $1K | |
| 82465 | <1% | 81 | $1K | |
| 82550 | <1% | 59 | $1K | |
| 83516 | <1% | 75 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 284 | $1K |
| 83605 | <1% | 41 | $1K | |
| 80180 | <1% | 44 | $1K | |
| 82104 | <1% | 21 | $1K | |
| 51728 | <1% | 13 | $1K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 5,767 | $1K |
| 80339 | <1% | 30 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 497 | $1K |
| 86704 | <1% | 40 | $1K | |
| 94664 | <1% | 1,722 | $1K | |
| 86480 | <1% | 14 | $1K | |
| 86708 | <1% | 27 | $910.88 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,801 | $905.46 |
| 51797 | <1% | 13 | $849.47 | |
| 92583 | <1% | 40 | $842.12 | |
| 93788 | <1% | 41 | $807.85 | |
| 82390 | <1% | 21 | $801.34 | |
| 97124 | <1% | 26 | $786.28 | |
| 84702 | <1% | 46 | $619.74 | |
| A9150 | Non-prescription drugs | <1% | 206 | $608.01 |
| 36592 | <1% | 163 | $602.86 | |
| 0051A | <1% | 38 | $599.82 | |
| 86709 | <1% | 13 | $588.16 | |
| 84703 | <1% | 53 | $544.35 | |
| 84156 | <1% | 25 | $489.16 | |
| 0173A | <1% | 24 | $482.99 | |
| 88311 | <1% | 13 | $459.22 | |
| 82330 | <1% | 13 | $441.64 | |
| 0052A | <1% | 25 | $406.79 | |
| J0290 | Injection, ampicillin sodium, 500 mg | <1% | 39 | $396.68 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 14 | $379.75 |
| J9370 | Vincristine sulfate, 1 mg | <1% | 17 | $365.79 |
| 86376 | <1% | 13 | $363.66 | |
| 86317 | <1% | 15 | $358.71 | |
| 99241 | <1% | 33 | $342.88 | |
| 86880 | <1% | 80 | $327.34 | |
| V5275 | Ear impression, each | <1% | 13 | $310.42 |
| 85018 | <1% | 50 | $309.93 | |
| 92002 | <1% | 52 | $296.05 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 20 | $280.22 |
| 90791 | Psychiatric diagnostic evaluation | <1% | 51 | $210.83 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 13 | $188.51 |
| 85651 | <1% | 60 | $188.36 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 33 | $176.20 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 25 | $167.84 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 13 | $153.06 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 14 | $110.93 |
| 86703 | <1% | 13 | $96.88 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 16 | $89.57 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 98 | $67.87 |
| 86780 | <1% | 13 | $59.10 | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 12 | $52.97 |
| 91307 | 0% | 2,058 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 178 | $0.00 |
| 91305 | 0% | 786 | $0.00 | |
| 91315 | 0% | 188 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 76 | $0.00 |
| C1769 | Guide wire | 0% | 28 | $0.00 |
| 91317 | 0% | 24 | $0.00 | |
| 91308 | 0% | 1,988 | $0.00 | |
| 91312 | 0% | 294 | $0.00 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 0% | 13 | $0.00 |
| 91311 | 0% | 788 | $0.00 | |
| G0390 | Trauma response team associated with hospital critical care service | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGAGE, WELDON (EXECUTIVE VICE PRESIDENT/CFO)
| Provider | Location | Paid |
|---|---|---|
| Texas Children's Physician Group | Houston, TX | $160.81M |
| Children's Health System | Milwaukee, WI | $553K |
| Children's Hospital of Wisconsin | Kenosha, WI | $50K |
| Children's Hospital of Wisconsin | Green Bay, WI | $24K |
| Children's Hospital of Wisconsin | Racine, WI | $10K |
| Children's Hospital of Wisconsin | Appleton, WI | $9K |
| Children's Hospital of Wisconsin | Waukesha, WI | $2K |
| Texas Children's Hospital | Austin, TX | $141.20 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.